{"nctId":"NCT01297920","briefTitle":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","startDateStruct":{"date":"2011-03"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"count":1062,"armGroups":[{"label":"Brinz/Brim","type":"EXPERIMENTAL","interventionNames":["Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension"]},{"label":"Brinzolamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Brinzolamide ophthalmic suspension, 1%"]},{"label":"Brimonidine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Brimonidine tartrate ophthalmic solution, 0.2%"]}],"interventions":[{"name":"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension","otherNames":[]},{"name":"Brinzolamide ophthalmic suspension, 1%","otherNames":[]},{"name":"Brimonidine tartrate ophthalmic solution, 0.2%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sign Informed Consent document.\n* Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s.\n* Other protocol-specified inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Females of childbearing potential if pregnant, lactating, or not using highly effective birth control measures.\n* Any form of glaucoma other than open-angle glaucoma.\n* Severe central vision loss in either eye.\n* Chronic, recurrent, or severe inflammatory eye disease.\n* Ocular trauma within the preceding 6 months.\n* Ocular infection or ocular inflammation within the preceding 3 months.\n* Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.\n* Best-corrected visual acuity score worse than 55 letters using the Early Treatment Diabetic Retinopathy Study chart.\n* Other ocular pathology (including severe dry eye) that may, in the opinion of the Investigator, preclude the administration of study product.\n* Ocular surgery within the preceding 6 months.\n* Ocular laser surgery within the preceding 3 months.\n* Any abnormality preventing reliable applanation tonometry.\n* Any other conditions, including severe illness, which could make the subject, in the opinion of the Investigator, unsuitable for the study.\n* Other protocol-specified exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3","description":"The study drug was instilled at 8 AM and 3 PM (approximately 15 minutes after conducting the IOP measurements). Intraocular pressure was measured by Goldmann applanation tonometry. One eye from each patient was chosen as the study eye and only data for the study eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":"0.30"},{"groupId":"OG001","value":"22.0","spread":"0.29"},{"groupId":"OG002","value":"23.2","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.30"},{"groupId":"OG001","value":"20.8","spread":"0.29"},{"groupId":"OG002","value":"19.9","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"0.30"},{"groupId":"OG001","value":"20.7","spread":"0.29"},{"groupId":"OG002","value":"21.5","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"0.30"},{"groupId":"OG001","value":"20.4","spread":"0.29"},{"groupId":"OG002","value":"18.9","spread":"0.30"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":221},"commonTop":["Dysgeusia","Conjunctivitis","Vision blurred","Eye irritation","Eye allergy"]}}}